Zacks Research Upgrades Nautilus Biotechnology (NASDAQ:NAUT) to “Hold”

Nautilus Biotechnology (NASDAQ:NAUT) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research note issued on Wednesday, Zacks reports.

Several other research analysts have also issued reports on NAUT. Weiss Ratings lowered shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Roth Capital began coverage on Nautilus Biotechnology in a research report on Tuesday. They set a “buy” rating and a $3.50 price objective for the company. Finally, Leerink Partners assumed coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Nautilus Biotechnology presently has an average rating of “Moderate Buy” and a consensus price target of $3.83.

Nautilus Biotechnology Trading Up 10.6%

Shares of NAUT stock opened at $1.57 on Wednesday. The firm’s fifty day simple moving average is $1.01 and its 200 day simple moving average is $2.01. The firm has a market capitalization of $199.78 million, a P/E ratio of -3.49 and a beta of 0.73. Nautilus Biotechnology has a 1 year low of $0.82 and a 1 year high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its earnings results on Monday, July 27th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.10 million. Equities research analysts anticipate that Nautilus Biotechnology will post -0.52 EPS for the current fiscal year.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in shares of Nautilus Biotechnology by 2.2% during the first quarter. Renaissance Technologies LLC now owns 265,700 shares of the company’s stock valued at $1,031,000 after purchasing an additional 5,800 shares in the last quarter. CTC Alternative Strategies Ltd. purchased a new stake in shares of Nautilus Biotechnology during the first quarter valued at approximately $48,000. TD Waterhouse Canada Inc. boosted its stake in Nautilus Biotechnology by 1,500.0% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock valued at $29,000 after purchasing an additional 15,000 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in Nautilus Biotechnology in the 1st quarter worth about $75,000. Finally, Callan Family Office LLC bought a new stake in shares of Nautilus Biotechnology in the second quarter worth approximately $49,000. Institutional investors and hedge funds own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.